-
公开(公告)号:JP5356864B2
公开(公告)日:2013-12-04
申请号:JP2009050728
申请日:2009-03-04
Applicant: 山本化成株式会社
Inventor: 正勝 中塚
IPC: H01L51/30 , C07D311/92 , C07D311/94 , C07D335/08 , C07D409/04 , H01L29/786 , H01L51/05
Abstract: PROBLEM TO BE SOLVED: To provide an organic transistor having high mobility, a large current on/off-ratio, and excellent in storage stability. SOLUTION: The organic transistor has an organic semiconductor layer which contains at least one kind of a compound represented by general formula (1). In the general formula (1), X 1 -X 18 are each independently a hydrogen atom, a halogen atom, a straight chain, branched or cyclic alkyl group, a straight chain, branched or cyclic alkoxy group, or a substituted or unsubstituted aryl group. Y 1 and Y 2 are each independently an oxygen atom or sulfur atom, and m and n are each independently 0 or 1. COPYRIGHT: (C)2010,JPO&INPIT
-
公开(公告)号:JP2010205985A
公开(公告)日:2010-09-16
申请号:JP2009050728
申请日:2009-03-04
Applicant: Mitsui Chemicals Inc , 三井化学株式会社
Inventor: NAKATSUKA MASAKATSU
IPC: H01L51/30 , C07D311/92 , C07D311/94 , C07D335/08 , C07D409/04 , H01L29/786 , H01L51/05
Abstract: PROBLEM TO BE SOLVED: To provide an organic transistor having high mobility, a large current on/off-ratio, and excellent in storage stability. SOLUTION: The organic transistor has an organic semiconductor layer which contains at least one kind of a compound represented by general formula (1). In the general formula (1), X 1 -X 18 are each independently a hydrogen atom, a halogen atom, a straight chain, branched or cyclic alkyl group, a straight chain, branched or cyclic alkoxy group, or a substituted or unsubstituted aryl group. Y 1 and Y 2 are each independently an oxygen atom or sulfur atom, and m and n are each independently 0 or 1. COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation: 解决的问题:提供高迁移率的有机晶体管,大的电流开/关比,并且存储稳定性优异。 解决方案:有机晶体管具有含有至少一种通式(1)表示的化合物的有机半导体层。 在通式(1)中,X 1 SB> -X SB 18各自独立地为氢原子,卤原子,直链,支链或环状烷基,直链 链,支链或环状烷氧基,或取代或未取代的芳基。 Y
1 SB>和Y 2 SB>各自独立地为氧原子或硫原子,m和n各自独立地为0或1.版权所有(C)2010, JPO&INPIT -
33.
公开(公告)号:JP2010510984A
公开(公告)日:2010-04-08
申请号:JP2009538341
申请日:2007-11-26
Applicant: ケーティ アンド ジー カンパニー リミテッド , マゼンス インコーポレイテッド
IPC: A61K31/352 , A61K9/14 , A61K31/343 , A61K31/381 , A61K31/382 , A61K31/39 , A61P15/10 , C07D307/77 , C07D307/92 , C07D311/78 , C07D311/92 , C07D311/96 , C07D327/06 , C07D333/74 , C07D335/08
Abstract: Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
-
公开(公告)号:JP2010510983A
公开(公告)日:2010-04-08
申请号:JP2009538340
申请日:2007-11-26
Applicant: ケーティ アンド ジー カンパニー リミテッド , マゼンス インコーポレイテッド
IPC: A61K31/343 , A61K31/352 , A61K31/381 , A61K31/382 , A61K47/04 , A61K47/32 , A61K47/36 , A61K47/38 , A61P13/08 , C07D307/77 , C07D307/92 , C07D311/78 , C07D311/92 , C07D311/96 , C07D327/04 , C07D327/06 , C07D333/74 , C07D335/08
Abstract: Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
-
公开(公告)号:JP2010510982A
公开(公告)日:2010-04-08
申请号:JP2009538339
申请日:2007-11-26
Applicant: ケーティ アンド ジー カンパニー リミテッド , マゼンス インコーポレイテッド
IPC: A61K31/4178 , A61K9/14 , A61K9/22 , A61K31/343 , A61K31/352 , A61K31/381 , A61K31/382 , A61K31/39 , A61P9/10 , A61P43/00 , C07D307/77 , C07D307/92 , C07D311/92 , C07D311/96 , C07D327/06 , C07D333/74 , C07D335/08 , C07D405/12
Abstract: Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.
-
公开(公告)号:JP2004043482A
公开(公告)日:2004-02-12
申请号:JP2003284757
申请日:2003-08-01
Applicant: Eisai Co Ltd , エーザイ株式会社
Inventor: YOSHIMURA HIROYUKI , NAGAI MITSUO , HIBI SHIGEKI , KIKUCHI KOICHI , HISHINUMA TAKAHARU , NAGAGAWA JUNICHI , ASADA MAKOTO , MIYAMOTO NORIMASA , HIDA TAKAYUKI , OGASAWARA AICHI , YAMATSU ISAO
IPC: C07D335/08 , A61K31/34 , A61K31/343 , A61K31/38 , A61K31/381 , A61K31/382 , A61K31/40 , A61K31/403 , A61K31/415 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/425 , A61K31/428 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/47 , A61K31/473 , A61P1/16 , A61P5/12 , A61P17/00 , A61P17/14 , A61P19/00 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C69/76 , C07C211/31 , C07D209/56 , C07D209/58 , C07D215/04 , C07D221/06 , C07D221/16 , C07D221/18 , C07D231/54 , C07D235/02 , C07D261/20 , C07D277/60 , C07D307/77 , C07D307/92 , C07D311/92 , C07D333/38 , C07D333/50 , C07D335/06 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D491/052 , C07D493/04 , C07D495/04 , C07D498/04 , C07D513/04
CPC classification number: C07D495/04 , C07D209/56 , C07D221/18 , C07D231/54 , C07D277/60 , C07D307/77 , C07D311/92 , C07D333/38 , C07D333/50 , C07D335/08 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D417/04 , C07D491/04
Abstract: PROBLEM TO BE SOLVED: To obtain a synthetic intermediate of a compound having antagonistic action an retinoids.
SOLUTION: A carboxylic acid derivative is expressed by formula (III) [wherein R
1 and R
2 express each a lower alkyl, or the like, or they together form a 5-7 membered cycloalkyl ring or a heterocycle derived by substituting carbon atoms forming the cycloalkyl ring with S, O, N, or the like; R
a and R
b express each H, a lower alkyl, or the like; A expresses O, S, N or CR
4 R
5 (R
4 and R
5 express each H, a lower alkyl, or the like), or the like; E expresses (CH
2 )n (wherein (n) expresses 0, 1 or 2), or the like; R
12 expresses two hydrogen atoms or a group selected from groups expressed by formula 3 (wherein R
13 and R
14 express each H or a lower alkyl)] or its physiologically permissible salt.
COPYRIGHT: (C)2004,JPO-
公开(公告)号:JP3273010B2
公开(公告)日:2002-04-08
申请号:JP1065498
申请日:1998-01-22
IPC: C07D295/08 , A61K31/10 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/35 , A61K31/352 , A61K31/38 , A61K31/382 , A61K31/40 , A61K31/4025 , A61K31/403 , A61K31/404 , A61K31/435 , A61K31/445 , A61K31/4453 , A61K31/452 , A61K31/4523 , A61K31/453 , A61K31/4535 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4725 , A61K31/535 , A61K31/5375 , A61K31/565 , A61K31/57 , A61P5/28 , A61P5/32 , A61P15/16 , A61P17/08 , A61P17/14 , A61P35/00 , C07C215/64 , C07C217/18 , C07C235/34 , C07C235/40 , C07C317/10 , C07C317/18 , C07D209/08 , C07D209/12 , C07D215/06 , C07D215/14 , C07D215/20 , C07D217/04 , C07D217/16 , C07D235/18 , C07D295/084 , C07D295/092 , C07D295/096 , C07D295/185 , C07D311/02 , C07D311/04 , C07D311/60 , C07D335/06 , C07D335/08 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D413/12 , C07J1/00 , C07J17/00 , C07J21/00 , C07J41/00 , C07J51/00 , C07J53/00 , C07J71/00
-
公开(公告)号:JP2002060384A
公开(公告)日:2002-02-26
申请号:JP2001207820
申请日:2001-07-09
Applicant: ENDORECH INC
Inventor: LABRIE FERNAND , MERAND YVES
IPC: C07D295/08 , A61K31/10 , A61K31/135 , A61K31/138 , A61K31/165 , A61K31/35 , A61K31/352 , A61K31/38 , A61K31/382 , A61K31/40 , A61K31/4025 , A61K31/403 , A61K31/404 , A61K31/435 , A61K31/445 , A61K31/4453 , A61K31/452 , A61K31/4523 , A61K31/453 , A61K31/4535 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/4725 , A61K31/535 , A61K31/5375 , A61K31/565 , A61K31/57 , A61P5/28 , A61P5/32 , A61P15/16 , A61P17/08 , A61P17/14 , A61P35/00 , C07C215/64 , C07C217/18 , C07C235/34 , C07C235/40 , C07C317/10 , C07C317/18 , C07D209/08 , C07D209/12 , C07D215/06 , C07D215/14 , C07D215/20 , C07D217/04 , C07D217/16 , C07D235/18 , C07D295/084 , C07D295/092 , C07D295/096 , C07D295/185 , C07D311/02 , C07D311/04 , C07D311/60 , C07D335/06 , C07D335/08 , C07D401/06 , C07D401/12 , C07D405/06 , C07D405/12 , C07D413/12 , C07J1/00 , C07J17/00 , C07J21/00 , C07J41/00 , C07J51/00 , C07J53/00 , C07J71/00
Abstract: PROBLEM TO BE SOLVED: To obtain a compound useful for treating breast cancer or other diseases promoted by their exacerbation due to the activation of sex steroid receptor, and to provide a medicament composition containing the above compound. SOLUTION: This compound has a general structure (A); wherein R1 and R2 are each a straight-chain or branched chain alkylene, phenylene, or the like; B is O, S, or the like; L is a moiety forming together with G a heterocyclic ring having at least one nitrogen atom, a lower alkyl, or the like; G is a moiety forming together with L a heterocyclic ring having at least one nitrogen atom, a lower alkyl, or the like; Z is a lower alkylene, O, S, or the like; R3 and R10 are each H, OH, or the like; and R6 is H, a lower alkyl, or the like. The compound can be used in medicament compositions either having anti-estrogenic activity or for inhibiting estrogen synthesis.
-
公开(公告)号:JP2001505914A
公开(公告)日:2001-05-08
申请号:JP52690498
申请日:1997-12-09
IPC: A61K31/192 , A61K31/235 , A61K31/352 , A61K31/381 , A61K31/382 , A61K31/44 , A61P1/00 , A61P3/06 , A61P9/00 , A61P17/00 , A61P25/28 , A61P27/00 , A61P29/00 , A61P31/12 , A61P35/00 , A61P37/00 , A61P43/00 , C07C45/00 , C07C47/548 , C07C61/08 , C07C61/29 , C07C69/00 , C07C69/74 , C07C69/78 , C07C233/00 , C07D213/55 , C07D311/92 , C07D333/24 , C07D335/08 , C07D409/06 , C07D417/02 , C07F7/02 , C07F7/08
-
公开(公告)号:JPH0665134A
公开(公告)日:1994-03-08
申请号:JP21767192
申请日:1992-08-17
Applicant: DAICEL CHEM
Inventor: TODA FUMIO
IPC: C07C49/747 , C07D207/02 , C07D209/66 , C07D307/92 , C07D335/08
Abstract: PURPOSE:To obtain an optically active compound, useful as a new optical record ing material or a reagent, etc., for optical resolution and having a new succinimide skeleton etc. CONSTITUTION:The objective optically active compound is expressed by formula I [X is =CH2, O, S or =NR (R is H or alkyl); A is aromatic group; Y is H or substituent group], e.g. a compound expressed by formula II. This optically active compound expressed by formula I is obtained by irradiating a new optically active precursor expressed by formula III with light. This optically active precursor expressed by formula III is obtained by adding acetic acid or an optically active compound to a racemic modification of a compound having the structure expressed by formula III.
-
-
-
-
-
-
-
-
-